CN EN JP
{pboot:sort scode=} [sort:name]
[sort:name]
{/pboot:sort}
{pboot:sort scode=}[sort:name]{/pboot:sort}
2024.07.10Phase I Clinical Trial of ZHB110 Sublingual Tablet (Antiallergic and Desensitizing Drug) Approved by the NMPA
On July 9, 2024,   ZHB110 sublingual tablet, a Class 1 new drug of therapeutic biological ···
2024.07.10ZHB103 Injection (CNS Drug) for a New Indication (TIA) Approved by the FDA
On July 9, 2024, the IND application of ZHB103 Injection, a Class 1 new drug of therapeutic biologic···
2024.01.31Phase I Clinical Trial Application of the Central Nervous System Drug ZHB103 for New Indication Approved by the FDA
On January 31, 2024, ZHB103 Injection, a new drug in Class 1 of therapeutic biologics originally dev···
2024.01.26The 2023 Annual Meeting and 2024 New Year Party of ZONHONBIO and GENSUNBIO Held Successfully
2024 is the year of dragon and the Chinese New Year is celebrated with singing and laughing. On Janu···
2024.01.24Phase I Clinical Trial Application of the Central Nervous System Drug ZHB103 Approved by the FDA
On January 24, 2024, the IND for ZHB103 Injection, a central nervous system drug originally develope···
2023.12.25Phase I Clinical Trial Application of the Central Nervous System Drug ZHB103 Approved by the NMPA
On December 25, 2023, ZHB103 Injection, a new drug in Class 1 of therapeutic biologics originally de···
2023.12.20Phase I Clinical Trial Application of the New Targeted Anti-tumor Drug ZHB114 Approved by the NMPA
On December 20, 2023, ZHB114 Injection, a new drug in Class 1 of therapeutic biologics originally de···
2023.12.13ZONHONBIO passing the re-evaluation of National High-tech Enterprise
On December the thirteenth 2023, Jiangsu ZONHONBIO passed the re-evaluation,receiving the title of N···